A complimentary breakfast seminar on Accelerated Development and Approval Pathways
This seminar is designed to help small and emerging companies understand each of the growing number of FDA expedited pathways, their comparative benefits and implications and their barriers to access.
Just as these new pathways continue to redefine how new treatments are developed and approved, the pathways themselves are evolving rapidly. While the pathways predominate in cancer, CNS, other disease areas, for example, they are more recently being applied to an ever-growing number of therapeutic areas, including diabetes and atopic dermatitis. And although each of the pathways have seen record growth from 2012-2016, we are also now seeing clear and shifting--but curious--patterns in their use by industry, particularly in areas such as oncology.